Loading company…
Reinovax Biologics develops vaccines and recombinant protein-based medicines.
Founded in 2017 and based in Shanghai, China, Reinovax Biologics develops and manufactures vaccines and recombinant protein-based biopharmaceuticals. Its pipeline includes PCV24, a pneumococcal conjugate vaccine in clinical trials, and a meningococcal vaccine; it also offers contract development and manufacturing services. The company raised CNY 200 million in Series B funding in January 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in